Loading stock data…
$2.10-0.03 (-1.40%)
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.
Xenetic Biosciences, Inc. in the Healthcare sector is trading at $2.09 with a market capitalization of $5M. The stock is currently near its 52-week low of $1.87, remaining 26.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $660,601↓ | $806,923↑ | $766,296↓ | $1.03M↑ | $589,897 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$971,690↓ | -$502,117↑ | -$623,027↓ | -$544,734↑ | -$724,412 |
| Net Income | -$929,695↓ | -$456,382↑ | -$579,076↓ | -$509,940↑ | -$688,703 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progr...